Chronic Gastritis Clinical Trial
Official title:
A Multicenter, Randomized, Open-label Phase IV Study Exploring Symptom Control Rate in Co-diagnosed NERD and Chronic Gastritis Patients Treated With 8 Weeks Esomeprazole Treatment Regimen and 2 Weeks Esomeprazole Treatment Regimen
Verified date | September 2012 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: Food and Drug Administration |
Study type | Interventional |
To compare the symptom control rate between 8 weeks esomeprazole treatment regimen group and 2 weeks esomeprazole treatment regimen group in co-diagnosed NERD and chronic gastritis patients, as evaluated by GerdQ after 24 weeks maintenance treatment/follow up.
Status | Completed |
Enrollment | 305 |
Est. completion date | June 2011 |
Est. primary completion date | June 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Heartburn and/or regurgitation symptoms last for at least 3 months - Endoscopic diagnosed as chronic gastritis (non-atrophic, and mild atrophic gastritis) within 2 weeks prior to randomization GerdQ score =8 Exclusion Criteria: - Endoscopic visible reflux esophagitis, esophageal varices, Barrett's esophagus, malignancy or peptic ulcer Patients with Hp positive result and are eager to take Hp eradication therapy will be excluded - If Hp positive, patients could take Hp eradication therapy after the study completion Previous PPI or H2RA therapy in the last 2 weeks before enrollment |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Research Site | Beijin | |
China | Research Site | Guangzhou | Guangdong |
China | Research Site | Hangzhou | Zhejiang |
China | Research Site | Jinan | Shandong |
China | Research Site | Nanjing | Jiangsu |
China | Research Site | Shanghai | |
China | Research Site | Wuhan | Hubei |
China | Research Site | Xian | Shanxi |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Symptom Control Rate at 24 Weeks Assessed by Gerd Q Questionnaire. | GerdQ Scores ranging from 0 to 3 were applied for the positive predictors and from 3 to 0 (reversed order, where 3 = none) for negative predictors. The GerdQ score was calculated as the sum of these scores, giving a total score ranging from 0 to 18. When GerdQ =8, the patients could be symptom based diagnosed as GERD. GerdQ was consisted of 3 categories: A, B and C. Each category has two questions with sum of score ranging from 0 to 6. Symptom controlled was defined as patients with all items =1 in A and C category of GerdQ. | 24 weeks | No |
Secondary | The Success Rate in Whole Study Duration. | Success is defined as patients with symptom relief after 8 weeks or 2 weeks esomeprazole treatment, and also get symptom controlled during maintenance treatment / follow-up period. | 24 weeks after end of treatment | No |
Secondary | Time to First Relapse. | Time to first relapse is from the last dose during the treatment period to date of first time patient comes to the investigator due to symptom recure and need for treatment. Time to first relapse is actually the time when 50% of patients had relapse. Up to the end of study, there were less than 50% of the patients in arm esomeprazole 2 weeks group had relapse so was unable to compute this endpoint |
From baseline to 24 weeks after end of treatment | No |
Secondary | Symptom Relief Rate in 2 Treatment Regimens. | Symptom relief is defined as no more than 1 day of mild symptoms of GERD during previous 7 days after 8 weeks or 2 weeks of treatment. | 8 weeks for arm 1, 2 weeks for arm 2 | No |
Secondary | Symptom Relief Rate After 2 Weeks and 8 Weeks in 8 Weeks Treatment Group. | Symptom relief is defined as no more than 1 day of mild symptoms of GERD during previous 7 days after 8 weeks or 2 weeks of treatment. | 2 and 8 weeks | No |
Secondary | Number of Patients With Unscheduled Hospital Visit(s) | from baseline to week 24 after end of treatment | No | |
Secondary | Percentage of Patients Satisfaction | Satisfied - satisfaction score of 1-4 while very satisfied - satisfaction score of 1-2. | 24 weeks after end of treatment | No |
Secondary | Symptom Control Rate at 8 Weeks Assessed by Gerd Q Questionnaire | GerdQ Scores ranging from 0 to 3 were applied for the positive predictors and from 3 to 0 (reversed order, where 3 = none) for negative predictors. The GerdQ score was calculated as the sum of these scores, giving a total score ranging from 0 to 18. When GerdQ =8, the patients could be symptom based diagnosed as GERD. GerdQ was consisted of 3 categories: A, B and C. Each category has two questions with sum of score ranging from 0 to 6. Symptom controlled was defined as patients with all items =1 in A and C category of GerdQ. | 8 weeks | No |
Secondary | Symptom Control Rate at 16 Weeks Assessed by Gerd Q Questionnaire | GerdQ Scores ranging from 0 to 3 were applied for the positive predictors and from 3 to 0 (reversed order, where 3 = none) for negative predictors. The GerdQ score was calculated as the sum of these scores, giving a total score ranging from 0 to 18. When GerdQ =8, the patients could be symptom based diagnosed as GERD. GerdQ was consisted of 3 categories: A, B and C. Each category has two questions with sum of score ranging from 0 to 6. Symptom controlled was defined as patients with all items =1 in A and C category of GerdQ. | 16 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04066530 -
A Study to Evaluate the Efficacy and Safety of AD-203
|
Phase 3 | |
Recruiting |
NCT05048069 -
Post-Marketing Surveillance of Safety and Effectiveness of Mucosta®SR Tab.
|
||
Completed |
NCT01817556 -
A Study to Evaluate the Efficacy and of Stillen Tab. and to Demonstrate the Non-inferiority of Stillen Tab.
|
Phase 4 | |
Recruiting |
NCT01813812 -
A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034
|
Phase 3 | |
Completed |
NCT00996788 -
Anti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis
|
Phase 3 | |
Completed |
NCT04341454 -
Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis
|
Phase 3 | |
Enrolling by invitation |
NCT05021029 -
A Study of Pre-Malignant Gastric Conditions
|
||
Completed |
NCT05073614 -
Evaluation of Immunohistochemical Expression of Heparanase in Helicobacter Pylori-Associated Chronic Gastritis
|
N/A | |
Completed |
NCT04697186 -
Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy
|
Phase 4 | |
Recruiting |
NCT00455806 -
Esomeprazole, Moxifloxacin and Amoxicilin for Rescue Therapy of Helicobacter Pylori Infection
|
Phase 3 | |
Recruiting |
NCT05666531 -
Research on Innovative Diagnosis and Treatment System of Syndrome Differentiation of Zang-fu Viscera and Effectiveness Evaluation Based on Inter-Arm Blood Pressure Measured Simultaneously
|
||
Completed |
NCT03847753 -
Exploring the Comorbidity Between Mental Disorders and General Medical Conditions
|
||
Completed |
NCT04189705 -
A Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis
|
Phase 3 | |
Completed |
NCT05014334 -
Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication
|
Phase 4 | |
Completed |
NCT02219529 -
Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases
|
Phase 3 | |
Completed |
NCT02356679 -
Efficacy and Safety of Eupasidin-s Tab.(EUPASIDIN-S) in Gastritis Patients
|
Phase 4 | |
Completed |
NCT03609892 -
Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy
|
Phase 4 | |
Unknown status |
NCT02282670 -
A Study to Evaluate the Efficacy and Safety of DA-5204
|
Phase 3 | |
Completed |
NCT02658864 -
Pharmacokinetic Properties and Effect of Food on Pharmacokinetic Properties of the Oral Lafutidine Tablets
|
Phase 1 |